Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The VANQUISH-1 trial enrolled approximately 4,650 adults with overweight or obesity without diabetes, and the VANQUISH-2 trial is currently enrolling about 1,100 adults with type 2 diabetes plus overweight or obesity
Lancet Diabetes Endocrinol 3(5):367381 van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH (2017) SGLT2 inhibition in the diabetic kidneyfrom mechanisms to clinical outcome
Discontinuation rates differ based on underlying medical conditions
The all-in-one approach simplifies the transition into GLP-1 therapy and ensures that basic nutritional gaps are covered from the start
The next few years will be critical in shaping this new landscape
For people with diabetes who are more likely to have a bone fracture, this neutrality is essential
